Celltrion Healthcare Co., Ltd.
091990
Rang in Aktien
#2133
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Aktienkurs
$57.75
Zuletzt synchronisiert: 2024-01-11
Marktkapitalisierung
$9.42B
Veränderung (1 Tag)
-0.25%
Veränderung (1 Jahr)
0.00%
Land
KR
Handel Celltrion Healthcare Co., Ltd. (091990)
Kategorie
Healthcare
P/S-Verhältnis für Celltrion Healthcare Co., Ltd. (091990)
P/S-Verhältnis zum October 2026 TTM: 5.44
Laut den neuesten Finanzberichten und dem Aktienkurs von Celltrion Healthcare Co., Ltd. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 5.44. Am Ende des Jahres 2021 lag das P/S-Verhältnis bei 7.25.
P/S-Verlauf für Celltrion Healthcare Co., Ltd. von 2014 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 5.44 | 16.07% |
| 2022 | 4.69 | -35.23% |
| 2021 | 7.25 | -17.28% |
| 2020 | 8.76 | -31.59% |
| 2019 | 12.81 | -35.25% |
| 2018 | 19.78 | 30.68% |
| 2017 | 15.14 | 12.59% |
| 2016 | 13.44 | -15.98% |
| 2015 | 16.00 | 9,049.06% |
| 2014 | 0.17 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.72 | 96.95% |
US
|
|
| 41.70 | 666.02% |
US
|
|
| 4.19 | -23.02% |
AU
|
|
| 5.80 | 6.46% |
BE
|
|
| 10.44 | 91.83% |
NL
|
